Ten to 20% of cases are due to inhibitory autoantibodies, predominantly against complement factor H (CFH), associated with biallelic deletions of CFHR3/1 (“DEAP HUS,” deficiency of CFHR proteins and CFH autoantibody positive) [6]. Here, CFH is linked to hemolytic-uremic syndrome.